Find Panobinostat lactate manufacturers, exporters & distributors on PharmaCompass

Panobinostat Lactate

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 USDMF, 2 EU WC, 1 NDC API

2 API Suppliers
1 USDMF
2 EU WC
1 NDC API

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

FINISHED DOSAGE FORMULATIONS

3 FDF Dossiers, 3 FDA Orange Book

3 FDF Dossiers
3 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 10MG BASE, CAPSULE;ORAL - EQ 15MG BASE, CAPSULE;ORAL - EQ 20MG BASE

drugProductComposition
CAPSULE;ORAL - EQ 10MG BASE
CAPSULE;ORAL - EQ 15MG BASE
CAPSULE;ORAL - EQ 20MG BASE

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 16 SPI Pharma, 3 Faran Shimi Pharmaceutical, 9 Gangwal Healthcare, 1 Pfanstiehl, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 2 DFE Pharma, 3 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 6 Kerry, 9 Microlex e.U, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 2 Prachin Chemical, 15 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 8 Sigachi Industries, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

48 Fillers, Diluents & Binders, 27 Direct Compression, 15 Co-Processed Excipients, 14 Chewable & Orodispersible Aids, 13 Taste Masking, 12 Thickeners and Stabilizers, 10 Lubricants & Glidants, 9 Disintegrants & Superdisintegrants, 9 Granulation, 5 Controlled & Modified Release, 4 Parenteral, 3 Coating Systems & Additives, 1 Film Formers & Plasticizers, 1 API Stability Enhancers, 1 Rheology Modifiers, 1 Emulsifying Agents

excipientsByApplications
48 Fillers, Diluents & Binders
27 Direct Compression
15 Co-Processed Excipients
14 Chewable & Orodispersible Aids
13 Taste Masking
12 Thickeners and Stabilizers
10 Lubricants & Glidants
9 Disintegrants & Superdisintegrants
9 Granulation
5 Controlled & Modified Release
4 Parenteral
3 Coating Systems & Additives
1 Film Formers & Plasticizers
1 API Stability Enhancers
1 Rheology Modifiers
1 Emulsifying Agents

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 11 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
11 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

PATENTS & EXCLUSIVITIES

6 US Patents

patents
6 US Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

9DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

348,504

Annual Reports (USD Million)

Finished Drug Prices

95 RELATED EXCIPIENT COMPANIES

173EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 960055-56-5, Panobinostat lactate [jan], Panobinostat (lactate), Hn0t99oo4v, Panobinostat lactate anhydrous, Chebi:85991

Molecular Formula

C₂₄H₂₉N₃O₅

Molecular Weight

439.5 g/mol

InChI Key

XVDWNSFFSMWXJJ-ASTDGNLGSA-N

FDA UNII

HN0T99OO4V

Panobinostat Lactate is the lactate form of panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, panobinostat selectively targets, binds to and inhibits HDAC, which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins.

1 2D Structure

Panobinostat lactate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide;2-hydroxypropanoic acid

2.1.2 InChI

InChI=1S/C21H23N3O2.C3H6O3/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26;1-2(4)3(5)6/h2-11,22-23,26H,12-14H2,1H3,(H,24,25);2,4H,1H3,(H,5,6)/b11-10+;

2.1.3 InChI Key

XVDWNSFFSMWXJJ-ASTDGNLGSA-N

2.1.4 Canonical SMILES

CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO.CC(C(=O)O)O

2.1.5 Isomeric SMILES

CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O

2.2 Other Identifiers

2.2.1 UNII

HN0T99OO4V

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 960055-56-5

2. Panobinostat Lactate [jan]

3. Panobinostat (lactate)

4. Hn0t99oo4v

5. Panobinostat Lactate Anhydrous

6. Chebi:85991

7. 960055-56-5 (lactate)

8. (e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide 2-hydroxypropanoate

9. Farydak (tn)

10. Panobinostat Lactate (jan)

11. (2e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino(methyl)phenyl)prop-2-enamide Mono((2rs)-2-hydroxypropanoate)

12. Propanoic Acid, 2-hydroxy-, Compd. With (2e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)-2-propenamide (1:1)

13. (2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide Lactic Acid

14. Unii-hn0t99oo4v

15. Propanoic Acid, 2-hydroxy-, Compd. With (2e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (1:1)

16. Panobinostat Dl-lactate

17. Schembl2315056

18. Schembl2315067

19. Chembl3545368

20. Dtxsid401026247

21. Bcp25197

22. Ex-a2659

23. Hy-10224a

24. Panobinostat Lactate [who-dd]

25. Panobinostat Lactate [orange Book]

26. Cs-0030991

27. D10019

28. A917191

29. Q27158837

30. (2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; 2-hydroxypropanoic Acid

31. (e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide2-hydroxypropanoate

32. (e)-n-hydroxy-3-[4-[[2-(2-methyl-1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide;2-hydroxypropanoic Acid

33. 2-hydroxypropanoic Acid--(2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide (1/1)

34. N-({4-[(1e)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]phenyl}methyl)-2-(2-methyl-1h-indol-3-yl)ethan-1-aminium 2-hydroxypropanoate

35. N-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) Ethyl]amino]methyl]phenyl]-2e-2-propenamide Dl-lactate Salt

36. N-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide Dl-lactate Salt

37. N-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide Lactate Salt

2.4 Create Date

2008-02-11

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₉N₃O₅
Molecular Weight	439.5 g/mol
Hydrogen Bond Donor Count	6
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	8
Exact Mass	439.21072103 g/mol
Monoisotopic Mass	439.21072103 g/mol
Topological Polar Surface Area	135 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	533
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.

5 Pharmacology and Biochemistry

5.1 ATC Code

L01XH03

API SUPPLIERS